TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum

Life sciences company Thermo Fisher (NYSE:TMO) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $12.14 billion. Its non-GAAP profit of $6.68 per share was 4.3% above analysts’ consensus estimates.